A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis - Extension study of PTC124 in Cystic Fibrosis

PTC Therapeutics, Inc.0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年5月6日

研究概览

暂无简介。

•1. Completion of ~48 weeks of blinded study drug treatment in the previous Phase 3 study
•(Study 009).
•2. Evidence of signed and dated informed consent/assent document(s) indicating that the
•subject (and/or his/her parent/legal guardian) has been informed of all pertinent aspects of
•the study. Note: If the study candidate is considered a child under local regulation, a
•parent or legal guardian must provide written consent prior to initiation of study
•screening procedures and the study candidate may be required to provide written assent.
•The rules of the responsible Institutional Review Board/Institutional Ethics Committee
•(IRB/IEC) regarding whether one or both parents must provide consent and the
•appropriate ages for obtaining consent and assent from the subject should be followed.
•3. In subjects who are sexually active, willingness to abstain from sexual intercourse or
•employ a highly effective barrier or medical method of contraception during ataluren administration and within 60 days of the last administration of the study drug.
•4. Willingness and ability to comply with scheduled visits, ataluren administration plan, study
•procedures, laboratory tests, and study restrictions.

•1. Known hypersensitivity to any of the ingredients or excipients of the study drug
•(polydextrose, polyethylene glycol, poloxamer, mannitol, crospovidone, hydroxyethyl cellulose, vanilla, colloidal silica, magnesium stearate).
•2. Current pregnancy or lactating, or pregnancy or lactating during the preceding Phase 3
•study (Study 009).
•3. Ongoing participation in any other therapeutic clinical trial.
•4. Prior or ongoing medical condition (eg, concomitant illness, psychiatric condition,
•behavioral disorder, alcoholism, drug abuse), medical history, physical findings, ECG
•findings, or laboratory abnormality that, in the investigator*s opinion, could adversely
•affect the safety of the subject, makes it unlikely that the course of treatment or follow-up
•would be completed, or could impair the assessment of study results.

发起方